Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review

CONCLUSION: Delayed thrombocytopenia, probably due to immune reaction, is a possible life-threatening adverse effect of ABX with a mean TTO of 9 days, supporting the recommendation of a platelet count monitoring during at least two weeks. This recommendation was added to the abcximab SmPC in 2019.PMID:33726948 | DOI:10.1016/j.therap.2021.02.006

Source: Therapie - March 17, 2021 Category: Psychiatry & Psychology Authors: Louis Vincent Delphine Bourneau-Martin Ana ïs Maurier Marina Babin St éphane Delepine Dominique Helley Aur élie Grandvuillemin Laurence Lagarce Agn ès Lillo-Le Louët Marie Briet Source Type: research